BioCentury | May 7, 2015
Top Story

Alexion to acquire Synageva

...Sanofi (Euronext:SAN; NYSE:SNY); and Roche (SIX:ROG; OTCQX:RHHBY). Synageva completed a reverse merger in 2011 with Trimeris Inc....
BioCentury | Jan 2, 2012
Finance

Living creatively

...of strength, not desperation." In November, the rare disease company completed a reverse merger with Trimeris Inc....
...of cash. Trimeris also brought in a bunch of cash," she said. At Sept. 30, Trimeris...
BioCentury | Jan 2, 2012
Finance

Small-fry squashed

...Genzyme Corp. , Alexion Pharmaceuticals Inc. and Roche, completed a reverse merger in December with Trimeris Inc....
BioCentury | Nov 7, 2011
Company News

Synageva, Trimeris deal

...Synageva completed its merger with infectious disease company Trimeris in a stock deal. The combined company...
...NASDAQ under the symbol "GEVA" (see BioCentury, June 20). Synageva BioPharma Corp. , Lexington, Mass. Trimeris Inc....
BioCentury | Sep 15, 2011
Cover Story

New targets for HIV

...antagonist from Pfizer Inc. Fuzeon is an ˆ HIV gp41-targeting viral fusion inhibitor marketed by Trimeris Inc....
...San Diego, Calif. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Tobira Therapeutics Inc. , Manalapan, N.J. Trimeris Inc....
BioCentury | Jun 20, 2011
Company News

Synageva, Trimeris deal

...infectious disease company Trimeris in a stock deal. Synageva stockholders will own about 75%, while Trimeris...
...to be called Synageva BioPharma Corp. MTS Securities advised Trimeris. The combined company will use Trimeris'...
...Phase I testing to treat lysosomal acid lipase (LAL) deficiency (Wolman disease). At March 31, Trimeris...
BioCentury | Jun 9, 2011
Distillery Therapeutics

Indication: Infectious disease

...GlaxoSmithKline plc market the nucleoside analog reverse transcriptase inhibitor (NRTI) Zeffix 3TC to treat HIV/AIDS. Trimeris Inc....
BioCentury | Oct 11, 2010
Company News

Trimeris, Novartis, Roche deal

...analog based on HIV gp41 to treat HIV infection (see BioCentury, July 19, 1999). Separately, Trimeris...
...license to Trimeris and Roche, Novartis will receive about $2.6 million up front, which represents Trimeris'...
...million within and outside of the U.S. and Canada, respectively (see BioCentury, Dec. 3, 2007). Trimeris Inc....
BioCentury | Jun 3, 2010
Distillery Therapeutics

Indication: Infectious disease

...MPI-451936, a small molecule fusion inhibitor of gp41, is in preclinical testing to treat HIV. Trimeris Inc....
BioCentury | Mar 1, 2010
Finance

Earnings on deck

...NASDAQ:IART) 3/1 Pre $0.58 $0.53 9% Ipsen Group (Euronext:IPN) 3/1 Pre NA €1.75 (A) NA Trimeris Inc....
Items per page:
1 - 10 of 352
BioCentury | May 7, 2015
Top Story

Alexion to acquire Synageva

...Sanofi (Euronext:SAN; NYSE:SNY); and Roche (SIX:ROG; OTCQX:RHHBY). Synageva completed a reverse merger in 2011 with Trimeris Inc....
BioCentury | Jan 2, 2012
Finance

Living creatively

...of strength, not desperation." In November, the rare disease company completed a reverse merger with Trimeris Inc....
...of cash. Trimeris also brought in a bunch of cash," she said. At Sept. 30, Trimeris...
BioCentury | Jan 2, 2012
Finance

Small-fry squashed

...Genzyme Corp. , Alexion Pharmaceuticals Inc. and Roche, completed a reverse merger in December with Trimeris Inc....
BioCentury | Nov 7, 2011
Company News

Synageva, Trimeris deal

...Synageva completed its merger with infectious disease company Trimeris in a stock deal. The combined company...
...NASDAQ under the symbol "GEVA" (see BioCentury, June 20). Synageva BioPharma Corp. , Lexington, Mass. Trimeris Inc....
BioCentury | Sep 15, 2011
Cover Story

New targets for HIV

...antagonist from Pfizer Inc. Fuzeon is an ˆ HIV gp41-targeting viral fusion inhibitor marketed by Trimeris Inc....
...San Diego, Calif. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Tobira Therapeutics Inc. , Manalapan, N.J. Trimeris Inc....
BioCentury | Jun 20, 2011
Company News

Synageva, Trimeris deal

...infectious disease company Trimeris in a stock deal. Synageva stockholders will own about 75%, while Trimeris...
...to be called Synageva BioPharma Corp. MTS Securities advised Trimeris. The combined company will use Trimeris'...
...Phase I testing to treat lysosomal acid lipase (LAL) deficiency (Wolman disease). At March 31, Trimeris...
BioCentury | Jun 9, 2011
Distillery Therapeutics

Indication: Infectious disease

...GlaxoSmithKline plc market the nucleoside analog reverse transcriptase inhibitor (NRTI) Zeffix 3TC to treat HIV/AIDS. Trimeris Inc....
BioCentury | Oct 11, 2010
Company News

Trimeris, Novartis, Roche deal

...analog based on HIV gp41 to treat HIV infection (see BioCentury, July 19, 1999). Separately, Trimeris...
...license to Trimeris and Roche, Novartis will receive about $2.6 million up front, which represents Trimeris'...
...million within and outside of the U.S. and Canada, respectively (see BioCentury, Dec. 3, 2007). Trimeris Inc....
BioCentury | Jun 3, 2010
Distillery Therapeutics

Indication: Infectious disease

...MPI-451936, a small molecule fusion inhibitor of gp41, is in preclinical testing to treat HIV. Trimeris Inc....
BioCentury | Mar 1, 2010
Finance

Earnings on deck

...NASDAQ:IART) 3/1 Pre $0.58 $0.53 9% Ipsen Group (Euronext:IPN) 3/1 Pre NA €1.75 (A) NA Trimeris Inc....
Items per page:
1 - 10 of 352